Depomed falls on Abbott dispute
January 19, 2011 at 16:00 PM EST
Shares of Depomed tumble on news that Abbott Laboratories is balking on marketing its pain reliever DM-1796, which is up for FDA approval.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.